⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRIX News
Nurix Therapeutics, Inc. Common stock
Form 8-K
sec.gov
NRIX
Molecular Glues Competitive Landscape Research Report 2026: Comprehensive Insights About 80+ Companies and 90+ Drugs
globenewswire.com
BMY
RVMD
NRIX
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
globenewswire.com
NRIX
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
prnewswire.com
ONCY
NRIX
ERAS
FHTX
ORIC
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
globenewswire.com
NRIX
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
NRIX
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
globenewswire.com
GTBP
LYEL
CRBU
SLS
NRIX
Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
globenewswire.com
NRIX
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual
globenewswire.com
NRIX
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
globenewswire.com
NRIX